IPO Journey
Kardigan, Inc.
IPO Date: June 18, 2026 · 3 filings tracked
Final Offer Terms
Ticker
KARD
Exchange
Nasdaq Global Market
Offer Price
$16.00
Shares Offered
25,000,000
Estimated Proceeds
$400.0M
Underwriters
Led by J.P. Morgan, Jefferies
Leerink PartnersTD Cowen
Filing Timeline
1
S-1
May 26, 2026
- Proprietary 'Prolaio' platform utilizes wearable sensors and AI to optimize clinical trial efficiency.
- Leadership team consists of industry veterans with a proven track record of FDA drug approvals.
2
S-1/A
June 11, 2026
- Led by a veteran management team with a proven track record of successful drug development and FDA approvals.
- Utilizes the proprietary 'Prolaio' platform, integrating wearable sensors and AI to accelerate clinical trial data collection.
Changes from previous filing
- ▸ Expected offer range: $14.0 – $16.0 per share
- ▸ Shares offered: 23,333,334
- ▸ Estimated proceeds: $326M
424B4
Final Pricing
June 18, 2026
- Leverages the 'Prolaio' platform, combining AI and wearable tech to modernize heart disease clinical trials.
- Pipeline features three distinct drug candidates targeting genetic heart muscle disease, valve issues, and hypertension.
Changes from previous filing
- ▸ Price range removed
- ▸ Final offer price: $16.0 per share
- ▸ Shares offered: 25,000,000
- ▸ Estimated proceeds: $400M
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.